FAILURE OF MIF-I TO AFFECT BEHAVIORAL-RESPONSES IN PATIENTS WITH PARKINSONS-DISEASE UNDER L-DOPA THERAPY

In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus. © 1979 Springer-Verlag.